American Society of Hirudotherapy

Current concepts in salvage procedures for failing microvascular flaps: is there a superior technique? Insights from a systematic review of the literature

Troeltzsch M, Troeltzsch M, Probst FA, Ristow O, Ehrenfeld M, Otto S (2016) · International Journal of Oral and Maxillofacial Surgery · n=330

Review: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Design
systematic review of 39 studies (330 microvascular free flap salvage cases) published between 1990 and 2015, with predefined inclusion/exclusion criteria and pooled descriptive analysis of salvage techniques; 11 leech-therapy studies (73 flaps) included (LMU Munich, University Goettingen, University Heidelberg)
Pooled sample (n; included studies may overlap)
330
Scope
Comparative assessment across four primary salvage techniques: (1) Fogarty catheter thrombectomy (6 studies, 68 flaps), (2) intraoperative thrombolytic drugs (16 studies, 184 flaps), (3) placement of an arteriovenous fistula (5 case reports, 5 flaps), and (4) postoperative medicinal leech therapy (11 studies, 73 flaps)
Main result
Pooled flap salvage success rates were broadly comparable across all four techniques with no single approach demonstrating clear superiority over the others; total reported sample limited to 330 flaps across 39 studies; only 5 of 39 included studies had control groups; level of evidence was uniformly low; the authors concluded that no superior salvage technique was identifiable from the existing evidence base

Key Findings

  • Largest pooled flap salvage systematic review at time of publication (39 studies, 330 flaps, 1990-2015)
  • Leech therapy was 1 of 4 main salvage techniques and contributed 11 studies / 73 flaps to the dataset
  • No salvage technique demonstrated clear superiority — emphasizes that leech therapy is a reasonable, evidence-supported option among several
  • Only 5 of 39 studies had control groups, exposing the methodological weakness of the salvage literature
  • Provides the strongest published basis for treating individual salvage technique selection as case-specific rather than algorithm-driven

Limitations

  • Pooled descriptive analysis only — no quantitative meta-analysis due to study heterogeneity
  • Underlying studies overwhelmingly low-quality with small samples and missing control groups
  • Publication and reporting bias likely (successful salvage cases over-represented)
  • Inclusion period ends in 2015 — does not capture more recent leech-therapy literature
  • Outcome adjudication varied widely across included studies

Clinical Implications

Troeltzsch 2016 is the definitive evidence-quality assessment of the flap-salvage literature through 2015 and concludes that the current published evidence cannot identify a superior salvage technique. For US clinicians, the review reinforces that medicinal leech therapy is one of the four established salvage options (alongside Fogarty thrombectomy, intraoperative thrombolytics, and arteriovenous fistula placement) and that local institutional expertise, patient-specific factors, and technique availability should drive case-by-case decisions. The review is also commonly cited to justify continued use of leech therapy as a legitimate K040187 technique pending higher-quality comparative trials.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.